 |
 |

Management of Clinically Localized Prostatic CancerAn Unresolved Problem
Willet F. Whitmore, Jr, MD
JAMA. 1993;269(20):2676-2677.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
 |
 |
Two timely and relevant reports concerning the management of clinically localized prostatic cancer are included in this issue of THE JOURNAL. The apparently rising incidence of and mortality with this neoplasm coupled with an expanding population and an increasing life expectancy have made prostatic cancer a major medical and socioeconomic problem. Recognized clinically primarily during the terminal third of the life span and characterized by an often protracted course, rational decisions regarding treatment are compromised by the inability to predict reliably either the life expectancy of the individual host or the natural course of the particular neoplasm. Confounding therapeutic decisions are long-persisting uncertainties regarding the relative merits of surgical excision, irradiation, and watchful waiting, not only with respect to cause-specific survival but also relative to the quality of life between diagnosis and death.
See also pp 2633 and 2650.
The report by Fleming et al1 uses decision analysis to
. . . [Full Text PDF of this Article]
Author Affiliations
From the Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY.
Footnotes
Reprint requests to Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021 (Dr Whitmore).
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
|